Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Apyx Medical (APYX) EPS (Weighted Average and Diluted) (2016 - 2024)

Apyx Medical (APYX) has disclosed EPS (Weighted Average and Diluted) for 15 consecutive years, with -$0.19 as the latest value for Q2 2024.

  • For the quarter ending Q2 2024, EPS (Weighted Average and Diluted) fell 533.33% year-over-year to -$0.19, compared with a TTM value of -$0.82 through Jun 2024, down 74.47%, and an annual FY2023 reading of -$0.54, up 19.4% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.19 for Q2 2024 at Apyx Medical, up from -$0.22 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.03 in Q2 2023 and bottomed at -$0.28 in Q4 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.14, with a median of -$0.14 recorded in 2020.
  • The sharpest move saw EPS (Weighted Average and Diluted) surged 99.95% in 2020, then crashed 533.33% in 2024.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.04 in 2020, then plummeted by 34.08% to -$0.06 in 2021, then crashed by 183.33% to -$0.17 in 2022, then tumbled by 64.71% to -$0.28 in 2023, then surged by 32.14% to -$0.19 in 2024.
  • Business Quant data shows EPS (Weighted Average and Diluted) for APYX at -$0.19 in Q2 2024, -$0.22 in Q1 2024, and -$0.28 in Q4 2023.